Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-blind, Placebo-controlled, Multi-Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SHR-1314 With Expanded Dose Finding in Subjects With Moderate-to-severe Plaque Psoriasis
Brief Summary: This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with moderate-to-severe plaque psoriasis.


Options:
A: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: CNTO 1959 (5 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (5 mg) | Arm Label: CNTO 1959 (15 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (15 mg) | Arm Label: CNTO 1959 (50 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (50 mg) | Arm Label: CNTO 1959 (100 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (100 mg) | Arm Label: CNTO 1959 (200 mg); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 (200 mg) | Arm Label: Adalimumab (approved psoriasis dosing); Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Arm Label: Placebo to CNTO 1959 (100 mg); Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1959 (100 mg), Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1959 (5 mg); Assigned to Arm(s): CNTO 1959 (5 mg) | Intervention Type: DRUG; Name: CNTO 1959 (15 mg); Assigned to Arm(s): CNTO 1959 (15 mg) | Intervention Type: DRUG; Name: CNTO 1959 (50 mg); Assigned to Arm(s): CNTO 1959 (50 mg) | Intervention Type: DRUG; Name: CNTO 1959 (100 mg); Assigned to Arm(s): CNTO 1959 (100 mg), Placebo to CNTO 1959 (100 mg) | Intervention Type: DRUG; Name: CNTO 1959 (200 mg); Assigned to Arm(s): CNTO 1959 (200 mg) | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab (approved psoriasis dosing) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo to CNTO 1959 (100 mg)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: 80mg SHR-1314-Part A; Type: EXPERIMENTAL; Interventions: Biological: SHR-1314, Drug: Placebo | Arm Label: 160mg SHR-1314-Part A; Type: EXPERIMENTAL; Interventions: Biological: SHR-1314, Drug: Placebo | Arm Label: 240mg SHR-1314-Part A; Type: EXPERIMENTAL; Interventions: Biological: SHR-1314, Drug: Placebo | Arm Label: 40mg SHR-1314 (Part B); Type: EXPERIMENTAL; Interventions: Biological: SHR-1314 | Arm Label: 80mg SHR-1314 (Part B); Type: EXPERIMENTAL; Interventions: Biological: SHR-1314 | Arm Label: 160mg SHR-1314 (Part B); Type: EXPERIMENTAL; Interventions: Biological: SHR-1314 | Arm Label: 240mg SHR-1314 (Part B); Type: EXPERIMENTAL; Interventions: Biological: SHR-1314 | Arm Label: SHR-1314 Placebo (Part B); Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: SHR-1314; Assigned to Arm(s): 160mg SHR-1314 (Part B), 160mg SHR-1314-Part A, 240mg SHR-1314 (Part B), 240mg SHR-1314-Part A, 40mg SHR-1314 (Part B), 80mg SHR-1314 (Part B), 80mg SHR-1314-Part A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 160mg SHR-1314-Part A, 240mg SHR-1314-Part A, 80mg SHR-1314-Part A, SHR-1314 Placebo (Part B)

Answer: D